FI945437A0 - Kiinteitä tebufelonidispersiokoostumuksia - Google Patents

Kiinteitä tebufelonidispersiokoostumuksia

Info

Publication number
FI945437A0
FI945437A0 FI945437A FI945437A FI945437A0 FI 945437 A0 FI945437 A0 FI 945437A0 FI 945437 A FI945437 A FI 945437A FI 945437 A FI945437 A FI 945437A FI 945437 A0 FI945437 A0 FI 945437A0
Authority
FI
Finland
Prior art keywords
tebufelon
solid
dispersion compositions
dispersion
compositions
Prior art date
Application number
FI945437A
Other languages
English (en)
Swedish (sv)
Other versions
FI945437A (fi
Inventor
Gary Robert Kelm
Douglas Joseph Dobrozsi
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of FI945437A0 publication Critical patent/FI945437A0/fi
Publication of FI945437A publication Critical patent/FI945437A/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI945437A 1992-05-19 1994-11-18 Kiinteitä tebufelonidispersiokoostumuksia FI945437A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/885,932 US5281420A (en) 1992-05-19 1992-05-19 Solid dispersion compositions of tebufelone
PCT/US1993/004050 WO1993023022A1 (en) 1992-05-19 1993-04-30 Solid dispersion compositions of tebufelone

Publications (2)

Publication Number Publication Date
FI945437A0 true FI945437A0 (fi) 1994-11-18
FI945437A FI945437A (fi) 1994-11-18

Family

ID=25388020

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945437A FI945437A (fi) 1992-05-19 1994-11-18 Kiinteitä tebufelonidispersiokoostumuksia

Country Status (6)

Country Link
US (1) US5281420A (fi)
EP (1) EP0641199A1 (fi)
JP (1) JPH10512845A (fi)
CA (1) CA2135603C (fi)
FI (1) FI945437A (fi)
WO (1) WO1993023022A1 (fi)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2281697A (en) 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
GB2289624B (en) * 1994-05-19 1998-03-18 Euro Celtique Sa Laxative compositions
DE19545043A1 (de) * 1995-12-02 1997-06-05 Scherer Gmbh R P Pharmazeutische Präparate zur oralen Anwendung und Verfahren zu ihrer Herstellung
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
IE981008A1 (en) * 1998-12-02 2000-06-14 Fuisz Internat Ltd Microparticles Containing Water Insoluble Active Agents
FR2792546B1 (fr) * 1999-04-26 2003-01-03 Rhodia Chimie Sa Composition solide comprenant au moins un tensioactif a bas point de fusion
US6413537B1 (en) 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
DE60105996T2 (de) * 2000-04-03 2006-03-09 F. Hoffmann-La Roche Ag Konzentrierte lösungen von carvedilol
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20040067256A1 (en) * 2001-02-13 2004-04-08 Anne Juppo Novel modified release formulation
HU229938B1 (en) * 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
US7670626B2 (en) * 2001-07-02 2010-03-02 Merrion Research Iii Limited Delivery of a bioactive material
AP1758A (en) * 2001-09-10 2007-07-30 Tibotec Pharm Ltd Method for the preparation of hexahydro-furo [2,3-b]furan-3-ol.
MXPA04007438A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
US7423004B2 (en) 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
EP1653927B1 (en) * 2003-08-04 2012-01-11 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
PL1663216T3 (pl) 2003-08-29 2012-03-30 Veloxis Pharmaceuticals As Kompozycje o zmodyfikowanym uwalnianiu zawierające takrolimus
CN1859909B (zh) 2003-08-29 2011-04-06 生命周期药物公司 含有他克莫司的固态分散体
US20080109751A1 (en) * 2003-12-31 2008-05-08 Alias Systems Corp. Layer editor system for a pen-based computer
US20060177403A1 (en) * 2005-02-08 2006-08-10 L'oreal Cosmetic/dermatological compositions comprising a derivative of glucose and of vitamin F and A specific surfactant
FR2881647B1 (fr) * 2005-02-08 2007-03-30 Oreal Composition cosmetique ou dermatologique contenant un derive de glucose et de vitamine f et un tensioactif specifique
KR20070025070A (ko) * 2005-08-31 2007-03-08 주식회사 대웅제약 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법
DK1928427T3 (da) 2005-09-23 2010-03-08 Hoffmann La Roche Hidtil ukendt dosisformulering
NZ568700A (en) 2005-11-28 2012-03-30 Marinus Pharmaceuticals Solid stabilized particulate formulations comprising ganaxolone
LT2530083T (lt) 2006-09-22 2016-09-26 Pharmacyclics Llc Brutono tirozinkinazės inhibitoriai
AU2007312233B2 (en) * 2006-10-20 2012-09-20 Abbvie B.V. Micellar nanoparticles of chemical substances
US7923026B2 (en) * 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
DK2167033T3 (en) 2007-05-30 2017-08-14 Veloxis Pharmaceuticals As Once daily oral dosage form comprising tacrolism
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
MX2010002712A (es) 2007-09-10 2010-06-09 Calcimedica Inc Compuestos que modulan calcio intracelular.
EP2042165A1 (de) * 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Hot-Melt-Befüllte Weichkapseln
EP2321303B1 (en) 2008-08-27 2019-11-27 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
WO2011100975A2 (en) 2010-02-17 2011-08-25 Lifecycle Pharma A/S Stabilized tacrolimus composition
EA201201263A1 (ru) * 2010-03-08 2013-04-30 Рациофарм Гмбх Фармацевтическая композиция, содержащая этексилат дабигатрана
EP2558866B1 (en) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
CA2797533A1 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
ES2591004T3 (es) 2010-04-27 2016-11-24 Calcimedica, Inc. Compuestos moduladores del calcio intracelular
EP2609095A4 (en) 2010-08-27 2014-06-18 Calcimedica Inc COMPOUNDS MODULATING INTRACELLULAR CALCIUM
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
MX2016007111A (es) 2013-12-05 2016-08-11 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton.
EP3725311A1 (en) 2014-02-10 2020-10-21 Respivant Sciences GmbH Methods for the treatment of lung diseases with mast cell stabilizers
US20150224077A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the Treatment of Systemic Disorders Treatable with Mast Cell Stabilizers, including Mast Cell Related Disorders
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
US9757334B2 (en) 2014-07-02 2017-09-12 The Research Foundation For The State University Of New York Surfactant-stripped micelle compositions with high cargo to surfactant ratio
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
CA2977521C (en) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
EP3454945B1 (en) 2016-05-12 2022-01-19 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
JP2019516773A (ja) 2016-05-25 2019-06-20 コンセントリック アナルジジックス,インク. 改善された局所麻酔のための局所麻酔薬及び血管収縮薬と組み合わせたフェノールtrpv1アゴニストのプロドラッグ
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US11242323B2 (en) 2016-08-26 2022-02-08 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
WO2019094434A1 (en) 2017-11-07 2019-05-16 The Regents Of The University Of Michigan Therapeutic combination for treatment of cerebellar ataxia
JP7424637B2 (ja) 2017-11-10 2024-01-30 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ash1l分解剤及びそれを用いた治療方法
US11324729B2 (en) 2017-12-07 2022-05-10 The Regents Of The University Of Michigan NSD family inhibitors and methods of treatment therewith
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
EP3813784B1 (en) 2018-06-07 2024-01-10 The Regents Of The University Of Michigan Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith
CN113166051A (zh) 2018-07-27 2021-07-23 同心镇痛药物公司 酚类trpv1激动剂的聚乙二醇化前药
US20200069742A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
US20200108102A1 (en) 2018-10-03 2020-04-09 Myos Rens Technology Inc. Spray dried follistatin product
US10925904B2 (en) 2018-11-06 2021-02-23 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE MENIN-MLL INTERACTION INHIBITORS
US11833186B2 (en) 2019-02-01 2023-12-05 Myos Corp. Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
JP2022524243A (ja) 2019-03-15 2022-04-28 ユニサイシブ セラピューティクス インコーポレイテッド ニコランジル誘導体
CN116113406A (zh) 2020-07-10 2023-05-12 密歇根大学董事会 Gas41抑制剂及其使用方法
US20240124467A1 (en) 2020-12-16 2024-04-18 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2024086613A2 (en) 2022-10-19 2024-04-25 Myos Corp. Myogenic compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698822A (en) * 1951-04-28 1955-01-04 Fougera & Co Inc E Cardiac glycoside buccal composition
US2988484A (en) * 1956-07-24 1961-06-13 Drew & Co Inc E F Alcohol soluble pharmaceutical compositions
US3308217A (en) * 1965-02-09 1967-03-07 Lowy Lawrence Method of granulating materials for subsequent forming into tablets
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
US3857933A (en) * 1969-10-17 1974-12-31 Hoechst Ag Process for the manufacture of a drug dosage form permitting controlled release of active ingredient
US3867521A (en) * 1970-08-26 1975-02-18 Scherer Corp R P Method for absorption of drugs
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
JPS53107408A (en) * 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
GB1598458A (en) * 1977-04-01 1981-09-23 Hoechst Uk Ltd Tableting of microcapsules
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
JPS5618914A (en) * 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
US4454152A (en) * 1980-05-07 1984-06-12 Hoffmann-La Roche Inc. Methoxsalen dosage forms
JPS5953410A (ja) * 1982-09-20 1984-03-28 Fujisawa Pharmaceut Co Ltd 新型ソフトカプセル剤
LU84515A1 (fr) * 1982-12-09 1984-10-22 Oreal Composition stable pour corticotherapie locale a forte concentration hydrocortisone solubilisee
US4797288A (en) * 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
DE3437599A1 (de) * 1984-10-13 1986-04-17 Dolorgiet GmbH & Co KG, 5205 St Augustin Ibuprofen enthaltende weichgelatinekapseln und verfahren zu ihrer herstellung
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
JPS61221131A (ja) * 1985-03-28 1986-10-01 Eisai Co Ltd 吸収促進したユビデカレノン含有組成物
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US4708966A (en) * 1986-06-27 1987-11-24 The Procter & Gamble Company Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
CH668553A5 (de) * 1987-02-02 1989-01-13 Mepha Ag Arzneimittel mit verzoegerter wirkstofffreisetzung.
US4847071A (en) * 1987-10-22 1989-07-11 The Procter & Gamble Company Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent
US4847303A (en) * 1987-11-23 1989-07-11 The Procter & Gamble Company Tert-butylphenyl compounds useful as anti-inflammatory agents
US4849428A (en) * 1987-11-23 1989-07-18 The Procter & Gamble Company Cyclic anti-inflammatory derivatives of di-tert-butylphenol compounds, compositions and use
US4936074A (en) * 1988-11-17 1990-06-26 D. M. Graham Laboratories, Inc. Process for preparing solid encapsulated medicament
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
EP0431659B1 (en) * 1989-11-22 1994-04-20 The Procter & Gamble Company Pharmaceutical compositions of tebufelone

Also Published As

Publication number Publication date
JPH10512845A (ja) 1998-12-08
CA2135603A1 (en) 1993-11-25
EP0641199A1 (en) 1995-03-08
CA2135603C (en) 1998-09-22
WO1993023022A1 (en) 1993-11-25
US5281420A (en) 1994-01-25
FI945437A (fi) 1994-11-18

Similar Documents

Publication Publication Date Title
FI945437A (fi) Kiinteitä tebufelonidispersiokoostumuksia
DE69325158D1 (de) Photokromische Zusammensetzung
DE69423670T2 (de) Siloxy-aluminoxan-Zusammensetzungen
DE69326743T2 (de) Tintenzusammensetzungen
DE69311550T2 (de) Sulfopolymer/vanadiumoxid - antistatische zusammensetzungen
KR950703926A (ko) 화장제 조성물(Cosmetic Composition)
DE69305255D1 (de) Beschichtungszusammensetzungen
DE69314838D1 (de) Bindemittelzusammensetzung
DE69310957D1 (de) Organosiliconzusammensetzungen
NO933467D0 (no) Ioderte aroyloksykarboksamider
DE69123586T2 (de) Modifizierte Dispergierzusammensetzungen
ITMI920347A0 (it) Composizioni poliolefiniche termosaldabili
DE69313922D1 (de) Polypropylene-Copolyphthalamid Zusammensetzungen
BR9406627A (pt) Composições antiparasiticas
BR9307800A (pt) ComposiçÕes anticárie
DE69322346D1 (de) Fotoresist-Zusammensetzungen
DE69320891D1 (de) Pestizide Zusammensetzung
DE69217904T2 (de) Zusammensetzung
DE69123585T2 (de) Modifizierte Dispergierzusammensetzungen
DK0599461T3 (da) Hærdelige sammensætninger
EE9800168A (et) Tahked kompositsioonid
FI934360A (fi) Synergistiska antimalariakompositioner innehaollande benflumetol
NO934230D0 (no) Vaskemiddelblandinger
DE69322453D1 (de) Pigmentzusammensetzung
ITMI921277A0 (it) Composizioni fungicide